The Li-Fraumeni Syndrome (LFS) is a rare, dominantly inherited syndrome that features high risk of cancers in childhood and early adulthood. Aected families tend to develop bone and soft tissue sarcomas, breast cancers, brain tumors, leukemias, and adrenocortical carcinomas. In some kindreds, the genetic abnormality associated with this cancer phenotype is a heterozygous germline mutation in the p53 tumor suppressor gene. Recently, we identi®ed one patient who presented in early childhood with multiple primary cancers and who harbored three germline p53 alterations (R156H and R267Q on the maternal allele and R290H on the paternal allele). To classify the biologic eects of these alterations, functional properties of each of the p53 mutants were examined using in vitro assays of cellular growth suppression and transcriptional activation. Each amino acid substitution conferred partial or complete loss of wild-type p53 function, but the child completed normal embryonic development. This observation has not been previously reported in a human, but is consistent with observations of normal embryogenesis in p53-de®cient mice.
Introduction
The Li-Fraumeni Syndrome (LFS) is an autosomal dominant familial cancer disorder characterized by the diagnosis of bone or soft tissue sarcoma at an early age in an individual from a family with multiple members aected by a wide array of other cancers (Li and Fraumeni 1969a,b; Williams and Strong, 1985; Li, 1988) . The component tumors of LFS are bone and soft tissue sarcomas, breast cancers, brain tumors, leukemias, and adrenocortical carcinoma (Kleihues et al., 1997) . An LFS family is classically de®ned by the inclusion of one individual, the proband, diagnosed with sarcoma before 45 years of age, who has one ®rst degree relative with cancer before 45 years of age and another ®rst or second degree relative in the same parental lineage with any cancer diagnosed before 45, or with sarcoma at any age (Li, 1988) . The estimated disease penetrance is 50% by 30 years and 90% by 60 years of age (Williams and Strong, 1985) .
Many families have been studied that resemble LFS but do not ®t the original de®nition. These LFS-like (LFS-L) families either fail to meet one particular criterion of the classic de®nition or present with other less frequently observed malignancies, such as germ cell tumors, melanoma, prostatic or pancreatic cancer (Strong et al., 1987; Li, 1988; Hartley et al., 1989; Garber et al., 1990) . These tumors are now considered to be associated with LFS and others are being evaluated. Eorts have been made to de®ne LFS-L, but this term has been used by some to describe families with individuals who are ®rst or second degree relatives aected at any age (Eeles, 1995) and by others to describe LFS with an increased age restriction of 60 years (Birch et al., 1994) . Further molecular and epidemiologic studies are needed to clarify these distinctions.
Inactivion of the p53 tumor suppressor gene has been found in a wide variety of sporadic tumors, including rhabdomyosarcoma, osteosarcoma (Mulligan et al., 1990) , leukemia (Ahuja et al., 1989) , carcinomas of the lung (Takahashi et al., 1989) and breast (Osborne et al., 1991) , brain tumors (Mashiyama et al., 1991) , and colorectal cancer (Baker et al., 1989) . Germline p53 alterations have been observed in the majority of LFS families and in some LFS-L families (Malkin et al., 1990; reviewed in Malkin, 1998) . Although deletions, insertions and splice mutations have been observed, the majority of the p53 mutations reported in LFS and sporadic tumors are missense, giving rise to an altered protein (Hollstein et al., 1991; reviewed in Malkin, 1998) . Most germline mutations are found in four highly conserved regions of the protein: residues 117 ± 142, 171 ± 181, 234 ± 258 and 270 ± 286. The particularly high frequency of mutations reported at codons 175, 245, 248, 273 and 282 has led to their reference as`hot spots' and are similar to those found in sporadic tumors.
Because of its apparent involvement in the pathogenesis of numerous sporadic and hereditary cancers, the functions of the p53 protein have been widely studied. p53 plays a central role in the cellular response to DNA damage (Levine, 1997) . Wild-type p53 has been shown to be an important player in the G 1 /S cell cycle checkpoint (Kastan et al., 1991; Kuerbitz et al., 1992) , which involves induction of p21 WAF1/CIP1 (El-Deiry et al., 1993; Xiong et al., 1993) , an inhibitor of cyclin-dependent kinases (Cdks) (Harper et al., 1993; Dulic et al., 1994) . A link between the p53-dependent cell cycle checkpoint and DNA repair was established when it was demonstrated that ionizing radiation induction of GADD45, which binds PCNA to induce excision repair of damaged DNA (Smith et al., 1994) , is dependent on wild-type p53 . Recent evidence indicates that p53 may be involved in blocking cells at G 2/ M (Paules et al., 1995; Cross et al., 1995; Wang and Prives, 1995; Fukasawa et al., 1996) . In addition to its role in cell cycle regulation, p53 is also able to induce apoptosis (Yonish-Rouach et al., 1991; Shaw et al., 1992; Lowe et al., 1993) by regulating the expression of other target genes, such as bax and bcl-2 (Miyashita et al., 1994a; Miyashita and Reed, 1995) .
Some p53 mutants have simply lost their growth suppressive properties, but others are thought to inhibit the functions of the wild-type protein in à dominant negative' fashion through oligomerization (Farmer et al., 1992; Kern et al., 1992) . Furthermore, some mutants may have acquired a`gain of function', demonstrated by the conferring of increased tumorigenicity upon introduction of mutant p53 constructs into p53-de®cient cells (Dittmer et al., 1993) . Therefore, both dominant negative and gain of function mutations would be more carcinogenic than the loss of one p53 allele. This is well illustrated in the analysis of mice containing a mutant p53 transgene (Harvey et al., 1995) .
The relationship between the LFS phenotype and genotype has yet to be fully elucidated. The reported proportion of patients with`classic' LFS (Li, 1988) harboring germline p53 mutations has varied from 60 ± 80% (Birch et al., 1994; Frebourg et al., 1995; Varley et al., 1997) . Furthermore, the degree of tumorigenicity associated with dierent p53 mutants is poorly understood. As part of initial steps to better understand the mechanisms of action of p53 mutants in LFS and to permit predictive testing, we regularly evaluate DNA obtained from blood samples of LFS patients for the presence and type of p53 mutation. We report here an intriguing p53 genotype in a classical LFS family.
Results

Identi®cation of germline p53 mutations
DNA sequence analysis of the p53 gene in peripheral blood of an LFS patient revealed the presence of R156H, R267Q and R290H mutations. Plasmids containing exon 8 PCR products, ampli®ed from DNA from the child (the proband), obtained from a b Figure 1 (a) Pedigree of LFS family in which the proband harbors germline p53 mutations on both alleles. (b) Pedigree of an LFS-like family with the R290H germline mutation. BB, bilateral breast cancer at age 30; CNS-brain tumor; ME-melanoma; NSneuro®brosarcoma; OS, osteosarcoma; RMS, rhabdomyosarcoma; SS, soft tissue sarcoma. *, unaected female; & male with cancer; 1-deceased female Figure 2 Sequence of clones obtained from exons 5 and 8 from the proband. R, arginine; H, histidine; Q, glutamine; C, cytosine; T, thymine; A, adenine; :, direction of sense strand p53 compound heterozygosity in a child with LFS S Quesnel et al several bacterial clones harbored either an R267Q mutation or an R290H mutation; no clones contained both mutations and no clones contained only wild-type DNA sequence (Figure 1 ). Blood samples from his parents showed co-segregation of the R156H and R267Q mutant alleles in the mother, whereas the father harbored the R290H mutant allele. The extended pedigree of this LFS family is shown in Figure 2a . The proband is a child who developed a rhabdomyosarcoma in the right neck at age 2, a brain tumor at age 10, and has died at age 12. His mother had bilateral breast cancer at ages 35 and 43, and his father was unaected. No family history is available for the father. Figure 2b showed the pedigree of an LFS-L family, in which a R290H alteration has also been found in the germline of the proband, who developed a brain tumor at age 9. Her parents were unaected but the paternal grandfather died of brain tumor at age 40 and her paternal ®rst cousin died of a rhabdomyosarcoma at age 4. No samples were available for analysis from the relatives, but the pattern of cancers in the three aected family members suggests that the R290H mutation might be incompletely penetrant.
Eect of p53 variants on activation of transcription from RGC promoter in yeast
To examine the extent of loss of wild-type function, each of the three missense alterations were further characterized using in vitro functional assays. cDNA vectors were constructed by site-directed mutagenesis PCR to express R156H, R267Q and R290H mutants, as well as one that expresses both the R156H and R267Q mutations (R156H/R267Q ± to represent the corresponding allele of the proband). The eect of a b c d these alterations on protein function were studied using in vitro assays that assess the ability of p53 to suppress cellular growth and activate transcription. The mutants were ®rst assessed for their ability to bind DNA and activate transcription of a reporter gene, ADE2.
Binding of the wild-type p53 to an RGC binding site upstream of its promoter drives the expression of this gene and corrects the red phenotype of yeast defective in their ability to produce adenine (colonies will become white) (Flaman et al., 1995) . As shown in Figure 3 , R267Q and R156H/R267Q transformants retained the red mutant phenotype, indicating that these substitutions represent loss of function mutations for the ability of p53 to activate transcription from the RGC sequence. In contrast, the R290H and R156H transformants were white, indicating that these amino acid substitutions did not aect p53 activity. These results were con®rmed in a second laboratory (JF) that performed this assay using mRNA from the parents.
Expression of p53 and p21 WAF1/CIP1 in transfected Saos-2 cells
Since the DNA-binding properties of the p53 variants may be in¯uenced by the nature of the binding site, each variant was also tested for the ability to induce the expression of p21
, an important downstream target of p53 in inducing G 1 /S arrest (El-Deiry et al., 1993; Dulic et al., 1994) . Protein expression in p53-de®cient Saos-2 osteosarcoma cells (American Type Cell Culture) was analysed 48 h following transfection with the various p53 cDNA constructs and each transfection was performed in triplicate. Western blot analysis ( Figure 4 ) demonstrates that p53 protein is expressed by each of the p53 cDNA vectors in Saos-2 cells, but not in untransfected cells or in those transfected with the cDNA3 vector alone (with no insert). This con®rms that Saos-2 cells do not express p53 and therefore any that is detected is exogenously expressed from the transfected construct. The relative amount of p53 expressed by each construct was assessed by correcting for loading (% actin) and transfection eciency (% b-gal activity). To facilitate comparison between experiments, values are expressed as a percentage of the wild-type. For all analyses, a two-tailed t-test was used to determine whether each of the p53 variants is signi®cantly dierent from the wildtype. As shown in Table 1 , R267Q and R156H/R267Q variants result in levels of p53 protein that are similar to wild-type, while R156H and R290H variants give rise to signi®cantly lower levels of protein (P50.005 and P50.001, respectively).
As shown in Figure 4 , p21 WAF1/CIP1 is only induced in Saos-2 cells that have been transfected with p53 cDNA. p21 WAF1/CIP1 levels were analysed in two ways: ®rst, to assess the eciency of each mutant p53 protein to activate transcription, relative p21 WAF1/CIP1 levels were measured by optical densitometry and calculated as a fraction of p53 protein levels; second, to compare the actual amounts of p21 WAF1/CIP1 that result from each transfection, p21 WAF1/CIP1 levels were corrected for loading and transfection eciency. The latter analysis takes into account the ability to activate transcription as well as dierences in the amount of p53 present due to variations in protein stability. For both analyses, values were expressed as a percentage of the p21 WAF1/CIP1 found in wild-type transfectants. All p53 variants have a signi®cantly reduced ability to induce p21 WAF1/CIP1 (Table 1) . Dierences between the R156H and R290H variants and the wild-type were further WAF1/CIP1 result from transfection with wild-type p53 and levels vary among transfectants of dierent p53 constructs harboring dierent alterations The level of signi®cance for the dierence between each p53 variant and the wild-type p53 compound heterozygosity in a child with LFS S Quesnel et al increased when p21 WAF1/CIP1 values were not normalized for p53 levels.
Eect of p53 variants on growth of Saos-2 cells
In activating the transcription of several target genes, the ultimate eect of p53 is the suppression of tumor cell growth. Therefore, the p53 variants were assessed for the ability to inhibit the proliferation of Saos-2 cells. Growth suppression is manifested by a reduction in colony formation by cells transfected with p53. Expression vectors were stably transfected into Saos-2 cells by lipofection and selection in G418 for 3 weeks. Transfection of Saos-2 cells with the wild-type p53 cDNA vector resulted in a reduced plating eciency as compared to cells transfected with the cDNA 3 vector alone ( Figure 5 and Table 2 ), indicating that growth suppression is due to the expression of p53. The p53 mutants displayed a variation in their ability to suppress the growth of Saos-2 cells. To account for dierences in conditions for each experiment, the results were expressed as the number of colonies as a percentage of the control (cDNA 3 vector alone) and the average of this value was calculated for three dierent experiments ( Figure 6 and Table 3 ). Stable transfection of Saos-2 cells with the wild-type p53 construct resulted in 15.38+3.16% of the number of colonies formed by cDNA 3 transfectants. Stable transfection of the p53 V143A mutant and the R156H/R267Q mutant vector resulted in substantially higher numbers of colonies (103.65+8.86% and 97.12+11.78%, respectively), indicating that these mutants have lost the ability to suppress growth. The other p53 variants demonstrated a stronger ability to suppress the growth of Saos-2 cells: R156H was similar to the wild-type p53 (17.96+5.39%), R290H led to slightly lower growth suppression than the wildtype p53 (23.87+3.04%), and R267Q displayed a Figure 5 Colonies formed by 2610 5 Saos-2 cells transfected with various p53 cDNA expression constructs. Each set of transfected cells was split 1 : 3, grown in 500 mg/ml G418 for 3 weeks, and stained with methylene blue p53 compound heterozygosity in a child with LFS S Quesnel et al greater drop in the ability to suppress growth (37.87+3.82%).
A two-tailed t-test was used to determine whether each of the p53 variants were signi®cantly dierent from the wild-type in their ability to suppress the growth of Saos-2 cells (P values are listed in Table 2 ). In summary, only the V143A, R267Q and R156H/ R267Q mutants displayed a signi®cantly reduced growth suppressive ability (P50.001, P50.02 and P50.005, respectively) and the R290H variant demonstrated a reduction that was only signi®cant at p50.2. The R156H variant does not demonstrate results that are signi®cantly dierent from the wild-type (P40.5).
Discussion
Germline p53 mutations have been observed in the majority of families with Li-Fraumeni Syndrome. This report describes an aected child in an LFS family with germline alterations in both p53 alleles (R156H and R267Q on the maternal allele and R290H on the paternal allele). All three alterations are located in the highly conserved DNA binding domain, although residue 290 is found at the extreme 3'-end of this region. The R290H mutation has been observed previously on three occasions: (1) in a colorectal carcinoma (Lang et al., 1993) ; (2) in acute myelogenous leukemia cells (Hu et al., 1992) , in which the protein was shown to be recognized by the PAb 240 antibody that detects mutant p53 (Gannon et al., 1990; Milner and Medcalfe, 1991) ; and (3) in the germline of our previously unreported LFS family (Figure 2b ). The R267Q mutation has been reported in a breast cancer and in the germline of a non-LFS cancer family in which a variety of cancers (mostly breast cancer) were observed over three generations . The R156H alteration has not been reported previously.
Transient transfection of Saos-2 cells with mutant p53 constructs resulted in signi®cantly lower levels of activated p21 WAF1/CIP1 than in cells transfected with the wild-type cDNA. In contrast, the R156H and R290H variants demonstrate the normal functional activation of transcription from the RGC sequence in yeast. Another study has also demonstrated that some p53 mutants retain wild-type activity for transcriptional activation using a similar yeast assay as described here, yet have lost the ability to undergo G 1 arrest and to induce p21 WAF1/CIP1 or GADD45 following ionizing irradiation (O'Connor et al., 1997). However, a comparison between the two transcriptional assays is dicult because the yeast assay is not quantitative (results are all or nothing), whereas the Western analysis in Saos-2 cells can detect subtle dierences in various mutant forms of p53. It is possible that lower levels of p21 WAF1/CIP1 induction observed for the R156H and R290H variants would be sucient to cause the phenotypic color change in the yeast. However, if this were true, then a color change would also be expected in yeast transformed by the R267Q mutant (16% of wild-type).
The colony-forming assay, which measures the ability of p53 to suppress the growth of Saos-2 cells, reveals that the p53 variants studied here display a range of maintenance of functional integrity. Such a range for dierent p53 mutants has been observed by others (Diller et al., 1990; Frebourg et al., 1992; Crook et al., 1994; Ishioka et al., 1997) . Interestingly, transfection of the construct containing both the R156H and R267Q mutants, as on the maternal allele, resulted in a much higher number of colonies than with either mutant alone or what would be expected if the eects of each were additive. These mutants appear to enhance synergistically the mutant properties of the protein product, possibly through a conformational eect. One corollary of this conclusion has been previously observed in studies in which a second p53 mutation is able to work in cis to suppress the mutant phenotype (Brachman et al., 1997) .
Although the colony-forming assay is quantitative, the results dier slightly from those observed for the up-regulation of p21 WAF1/CIP1 . The R156H and R290H variants demonstrated no signi®cant reduction in the ability of wild-type p53 to suppress Saos-2 cell growth. Others have also observed discordance in retention of function as measured by the two assays. One study demonstrated that p53 cDNA constructs lacking domains necessary for growth suppression of H1299 exhibit wild-type transcriptional activation of a reporter gene using a CAT assay (Walker and Levine, 1996) . Another study demonstrated that a R273H/P309S p53 variant lost the ability to suppress the growth of several types of cell lines in spite of its wild-type ability to activate transcription from the RGC sequence, while a R273L variant maintained the ability to suppress growth in spite of having lost the ability to activate transcription (Kawamura et al., 1996) . Furthermore, oligomerization domain p53 mutants L344P and K351Ter, which are defective for transcriptional activation in Saos-2 cells, displayed the ability to inhibit colony formation in these cells (Ishioka et al., 1995 (Ishioka et al., , 1997 .
Perhaps the ability of p53 to activate transcription upon binding to one speci®c responsive element (RGC or p21 WAF1/CIP1 promoter) does not represent potential interactions with other p53 binding elements that may have important functional consequences for growth suppression, such as those upstream of target genes whose products are involved in apoptosis. Alternatively, it is possible that p53-dependent growth suppression of Saos-2 cells involves a mechanism that is independent of transcriptional activation, such as the repression of transcription.
It is dicult to compare the biological importance of results from the dierent assays used in this study. Although the RGC sequence exhibits strong binding to p53 (Kern et al., 1992; Kim et al., 1997) , the relevance of this interaction in vivo is not known. In contrast, the upregulation of p21 WAF1/CIP1 by binding of p53 to sequences upstream of its promoter is critical for its induction of G 1 /S arrest (El-Deiry et al., 1993; Dulic et al., 1994) . However, it is dicult to predict the biological consequence of the partial activity demonstrated by the R156H and R290H variants. The assays that measure activation of transcription from the RGC sequence and p21 WAF1/CIP1 promoter examine speci®c mechanisms of p53 action, whereas the growth suppression assay may represent other mechanisms and analyses a cellular phenotype. Thus, each assay has important, but dierent biological relevance.
This study demonstrates that the R156H/R267Q p53 allele inherited by the proband encodes a protein that p53 compound heterozygosity in a child with LFS S Quesnel et al is defective for transcriptional activation as well as growth suppression of Saos-2 cells. The other allele (R290H) gives rise to a protein that has maintained the ability to induce growth suppression of Saos-2 and activate transcription from the RGC sequence, but this ability is reduced for the p21 WAF1/CIP1 promoter. Although the R290H mutant may have less severe functional consequences than the R156H/R267Q allele, the relative severity of the consequences of these dierent mutations in this family are dicult to assess. It is possible that the aggressive cancer phenotype of the proband may be attributed to this unusual p53 genotype, in which each allele has lost partial or complete function. Also, the observation that the R290H alteration is less detrimental to p53 function may explain the pattern of incomplete penetrance found in the LFS-like cancer family (Figure 2b) .
The fetal development of the proband is consistent with similar observations in p53-de®cient mice, which are able to complete gestation and are usually born without any observable gross defects, but then rapidly develop a variety of tumors, including sarcomas and others commonly seen in LFS (Donehower et al., 1992; Purdie et al., 1994; Sah et al., 1995) . Therefore, although p53 plays a central role in cell cycle arrest and apoptosis in the cellular response to DNA damage, perhaps these functions are not essential in human embryogenesis. Alternatively, as with the Rb family, there may exist other proteins sharing properties similar to p53, such as p73, which has been shown to activate the transcription from p53 binding sequences and induce apoptosis in transiently transfected Saos-2 cells (Jost et al., 1997; Kaghad et al., 1997) . p53CP (p53 competing protein), another protein that has been recently isolated and characterized, demonstrates homology to p53 and the ability to bind speci®cally to the consensus p53 binding sites found in several p53 downstream target genes (Bian and Sun, 1997) . Perhaps there exist other homologous proteins or even pathways that have yet to be discovered that are redundant for the important functions of p53.
Materials and methods
Isolation of DNA from peripheral blood
Upon obtaining informed consent all eligible adults and from the parents of all eligible children, genomic DNA was extracted at the DFCI from peripheral blood leukocytes, using a Qiagen blood DNA isolation kit.
PCR ± SSCP and sequencing
Fluorescent automated sequencing (ABI) was performed at DFCI. As described previously (Peng et al., 1993) , PCR ± SSCP was performed on the isolated DNA spanning p53 exons 2 ± 11 at the HSC, and samples demonstrating reproducible band shifts were sequenced by the Sanger dideoxy method to characterize the precise base pair alterations.
Mutagenesis and construction of p53 expression vectors
Mutations were inserted into a p53 wild-type cDNA sequence using a PCR-based method of site-directed mutagenesis. Two PCR reactions were carried out, amplifying sequences both upstream and downstream of each mutation. For one reaction, a primer complementary to the antisense strand containing the mutation of interest [in bold] (5'-CACC-CACGTCCGCGCCATGGCC-3' for R156H, 5'-GGGACA-GAACAGCTTTGAGG-3' for R267Q, and 5'-GCACAGAGGAAGAGAATCTCCACAAG-3' for R290H) were used with a primer complementary to the sense strand downstream of the mutation (5'-AATGTCAGTCTGAGT-CAGGC-3' for all). For the other reaction, a primer complementary to the sense strand containing the mutation (5'-GGACGTGGGTGCCGGGCGGGGGTG-3' for R156H, 5'-CTGTTCTGTCCCAGTAGA-3' for R267Q), and a primer downstream of the mutation (5'-CTTGAGTTC-CAAGGCCTCATTCAGC-3' for R290H) were used with a primer complementary to the antisense strand upstream of the mutation (5'-AAGTCTAGAGCCACCGTCCA-3' for all). Each 100 ml PCR reaction consisted of 10 ng of p53 cDNA template, 500 ng of each primer, 200 mM dNTP's, 1.5 mM MgCl 2 , and 2.5 units of Taq polymerase (AmpliTaq; Cetus). The reaction conditions for the Perkin-Elmer 480 thermocycler (Norwalk, CT, USA) were: 948C for 45 s, 608C for 5 min and 728C for 2 min for 5 cycles, followed by: 948C for 45 s, 608C for 2 min, 728C for 2 min for 20 cycles, and then 728C for 10 min. Products from both reactions were puri®ed from agarose using Qiaex extraction (Qiagen) and 10 ml of each were then used together as the template in a second PCR reaction with the¯anking oligonucleotides primers used in ®rst PCR step (5'-AATGTCAGTCTGAGT-CAGGC-3' and 5'-AAGTCTAGAGCCACCGTCCA-3').
Other conditions remain the same as above except all 30 cycles followed the pro®le: 948C for 45 s, 608C for 2 min, 728C for 2 min, and then 728C for 10 min. The ®nal PCR product was puri®ed from agarose and each digested with dierent restriction enzymes: PvuII+Bsu36I for R156H, Bsu36I+StuI for R267Q, and StuI+EarI for R290H. Each fragment was subcloned into an appropriately digested WT p53cDNA 3 expression vector. The WT p53cDNA 3 was created by inserting WT p53 cDNA (a gift of Dr Stephen Friend) into the BamHI site of the pcDNA 3 pcDNA 3 plasmid (In Vitrogen). 1 ml calf intestinal phosphatase (CIP) was also included in the pcDNA 3 digest to prevent self-annealing. V143A cDNA was provided by Dr Sam Benchimol (Ontario Cancer Institute) and was inserted into cDNA3 in the same way. The R156H/R267Q double mutant was created by subcloning the R267Q mutant cDNA into a R156H p53cDNA 3 backbone that had been digested with Bsu36I+StuI. The pcDNA 3 plasmid carries a CMV promoter, driving the expression of the upstream p53 cDNA, as well as Ampicillin and Neomycin resistance genes. The presence of mutations in all constructs were veri®ed by sequence analysis.
Activation of transcription in yeast
All p53 cDNA constructs were analysed for their ability to bind to the ribosomal gene cluster (RGC) sequence and activate transcription of the ADE2 reporter gene in yeast. This was performed by OncorMed as described previously (Flaman et al., 1995) .
Cell culture and transfection
Saos-2 osteosarcoma cells were purchased from American Type Cell Culture and grown as monolayers in a-MEM with 10% fetal calf serum in a humidi®ed incubator at 378C and 5% CO 2 . Protein expression was analysed following transient transfection of Saos-2. 5610 5 cells were seeded onto 100 mm plates, incubated overnight at 378C, and washed with serumfree a-MEM without antibiotics. For each plate, 18.75 ml of Lipofectin Reagent was diluted in 375 ml of Opti-Mem I Medium and 7.5 mg each of p53 cDNA 3 and cDNA3/LacZ (In Vitrogen) were diluted together in 375 ml of Opti-Mem I p53 compound heterozygosity in a child with LFS S Quesnel et al
Medium and incubated at room temperature for 45 min. These were then mixed together and incubated further for 15 min at room temperature. Three ml of serum-free a-MEM was added to the above mixture, which was then added to washed cells, incubated overnight at 378C, and then replaced with 10 ml of medium containing 10% serum. Forty-eight hours later, cells were washed twice with PBS, and incubated in 100 ml modi®ed RIPA lysis buer (50 mM Tric-Cl pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5% sodium deoxycholate, 1% Triton X-100, 0.1% SDS, 1 mM PMSF, 2 mg/ml each leupeptin, pepstatin, aprotinin) on ice for 10 min. Cells were harvested by scraping them into a 1.5 ml microfuge tube and then sonicated with an XL-2020 ultrasonic processor (Misonix) using 20% power for 1 min. Transfection eciency was determined by measuring b-gal activity of each protein sample. A 20 ml aliquot of each cell lysate was removed prior to sonication, 10 mg of total protein was diluted to 20 ml in modi®ed RIPA buer, and transferred to a microtiter plate. The assay buer consisted of 1 ml of a 2 mg/ ml solution of the substrate ONPG (O-nitrophenyl b-Dgalactopyranoside), in freshly prepared 0.1 M NaPO 4 , added to 5 ml of b-gal buer (60 mM Na 2 HPO 4 , 40 mM NaH 2 PO 4 , 10 mM KCl, 1 mM MgCl 2 , 50 mM b-mercaptoethanol). 208 ml of the assay buer was mixed into each of the wells containing cell lysates and incubated at 378C until a yellow color developed (*1 h). 80 ml of 1 M Na 2 CO 3 was then mixed into each well and the absorbance was measured at 410 nm.
Western blotting
Forty mg total protein from each lysate separated on a 12.5% acrylamide gel, electroblotted onto nitrocellulose, and blocked in 5% Blotto for 1 h. The membrane was incubated overnight at 48C with the following mouse anti-human monoclonal antibodies: two p53 antibodies pAb 1801 and pAb DO-1 (1 : 200 for each, Oncogene Science, Ab-2 and Ab-6, respectively), a p21 Waf1/Cip1 antibody (1 : 100, Ab-1, Oncogene Science) and an actin antibody (1 : 400, Sigma). After washing and incubation with peroxidase-labeled goat anti-mouse IgG (H+L) secondary antibody (1 : 5000, KPL) for 1 h at room temperature, protein bands were detected using ECL (Enhanced Chemiluminescence, Amersham) according to the manufacturer's instructions. The signal for each protein band was quantitated using optical densitometry.
Stable transfection of Saos-2 and colony-forming assay
Transfections were performed on the same day using Saos-2 cells plated from the same stock. Two 6 10 5 cells were seeded onto 60 mm plates, incubated overnight at 378C, and washed with serum-free a-MEM without antibiotics. Transfections were carried out using Lipofectin (Gibco ± BRL). 10 ml of Lipofectin Reagent was diluted in 100 ml of Opti-Mem I medium and incubated at RT for 45 min. This was then mixed with 100 ml of Opti-Mem I medium containing 4 mg of p53 mutant construct and incubated further for 15 min at RT. 1.8 ml of serum-free a-MEM was added to above mixture, which was then incubated overnight at 378C with washed cells and then replaced with 4 ml of medium containing 10% serum. Forty-eight hours later, cells were split 1 : 3 into selection medium (a-MEM containing 10% serum and 500 mg/ml G418). After 3 weeks, colonies were stained with methylene blue and counted. Each set of transfections was done in triplicate on separate days yielding reproducible relative colony numbers.
